title: Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.
authors.affiliation: 1 Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA ; 2 Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Jody C
authors.initials: JC
authors.lastname: Chuang
authors.affiliation: 1 Division of Hematology and Oncology, Stanford Hospital & Clinics, Stanford, CA, USA ; 2 Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Joel W
authors.initials: JW
authors.lastname: Neal